ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0640

Multidisciplinary and Multiparametric Evaluation of Sarcopenia in Patients with Systemic Sclerosis

Marco Di Battista1, Alessandra Rossi1, Gaia Pisano1, Riccardo Morganti2, Alessandra Della Rossa3 and Marta Mosca4, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2Section of Statistics, University of Pisa, Pisa, Italy, 3University of Pisa, Rheumatology Unit, Pisa, Italy, 4Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Meeting: ACR Convergence 2023

Keywords: Muscle strength, nutrition, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease with a heterogeneous clinical expression that heavily affects the functionality and quality of life of patients. Sarcopenia is an insidious complication of SSc, often poorly recognized and underdiagnosed, but difficult to manage and with important prognostic repercussions. The aim of this study was to evaluate the prevalence of sarcopenia in subjects with SSc, trying to obtain a characterization as complete as possible through a multidisciplinary approach.

Methods: Consecutive adult SSc patients were evaluated by a multidisciplinary team of rheumatologists, nutritionists and physiotherapists to identify the presence of sarcopenia according to the diagnostic algorithm proposed by the EWGSOP2 consensus in 2019. After completing the SARC-F questionnaire, generally used for the case finding, the patients’ muscle strength was measured with the hand grip test and the 5-times sit to stand test (5STS). Subsequently, the confirmation of a possible sarcopenia was obtained by measuring the appendicular skeletal muscle mass (ASSM) by bioimpedance vector analysis (BIVA), a method also used to identify subjects with a state of malnutrition. Finally, the severity of sarcopenia was assessed using the following physical performance tests: short performance physical battery (SPPB – composite score of balance tests, 4m linear walk and 5STS), time up and go (TUG – static balance and dynamic) and gait speed.

Results: Thirty-three SSc patients (87.8% female, mean age 61.2 ± 12 years) were evaluated. The SARC-F questionnaire resulted pathological in 9 of them, whereas for the evaluation of muscle strength pathological values were observed in 42.4% and in 45.4% of the hand grip and 5STS tests, respectively. The ASSM/height ratio was used for the evaluation of muscle mass and was found pathologically reduced in 37.2% of patients. Finally, physical performance tests had pathological results in 27.2% of SPPB, 9% of TUG and 15.1% of gait speed tests. According to the definitions proposed by the EWGSOP2, in our cohort sarcopenia was found in 13 (39.4%) SSc patients, of which 5 (15.1%) presented a severe form. In addition, BIVA found malnutrition in 12 patients and this happened in combination with a sarcopenic state in 75% of cases. Malnourished subjects had significantly lower hand grip strength values (p=0.007), worse SPPB scores (p=0.03), and longer TUG times (p=0.05).

Conclusion: Sarcopenia emerges as a relatively frequent complication in SSc, with important repercussions on the physical-dynamic sphere and a profound interrelationship with nutritional status. A multidisciplinary approach is essential for an accurate diagnosis of sarcopenia in potentially high-risk individuals such as those with SSc.


Disclosures: M. Di Battista: None; A. Rossi: None; G. Pisano: None; R. Morganti: None; A. Della Rossa: None; M. Mosca: AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, GlaxoSmithKlein(GSK), 2, Otsuka, 2, UCB, 2.

To cite this abstract in AMA style:

Di Battista M, Rossi A, Pisano G, Morganti R, Della Rossa A, Mosca M. Multidisciplinary and Multiparametric Evaluation of Sarcopenia in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/multidisciplinary-and-multiparametric-evaluation-of-sarcopenia-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multidisciplinary-and-multiparametric-evaluation-of-sarcopenia-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology